Generated by AI
SI-BONE, Inc. is a medical device company focused on developing procedural solutions for musculoskeletal disorders of the sacropelvic anatomy. SI-BONE’s product portfolio centers on minimally invasive implant systems designed for sacroiliac joint fusion, pelvic fixation, and related orthopedic applications. Its offerings include patented titanium implants, surgical instruments, and implantable bone products used in procedures addressing sacroiliac joint dysfunction, pelvic trauma, and spinopelvic reconstruction. The company serves physicians and hospitals in the United States and selected international markets, supporting treatment workflows through direct sales and third-party distribution channels. Based in Santa Clara, California, SI-BONE plays a specialized role in the orthopedics and spine market by providing anatomy-specific technologies for patients with complex bone and joint conditions.
Website471 El Camino Real
Santa Clara, CA, 95050
United States
The latest articles about SIBN.
SI-BONE stock ripped higher, closing at US$23.77, up 17.6% on the first full trading day after its Q3 2026 report. Traders focused on the headline beat in procedure activity and adjusted EBITDA, rather than on the fact the business is still posting a net loss of US$3.6 million for the quarter. For a medtech growth story, the real hook is the profit trend. Revenue reached US$55.7 million in Q3, and trailing twelve month losses have been steadily shrinking. In the short term, the chart grabbed...
Summary of May 12's posts. Generated by AI.
No summary yet.
No summary yet.
Summary of Feb 28's posts. Generated by AI.
Summary of Feb 28's posts. Generated by AI.
Investors talking about SIBN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.